CymaBay Therapeutics will present results of its Phase 2 proof-of-concept MBX-8025
clinical trial at the Annual Meeting of the American Association for the Study of
Liver Diseases Nov. 11-15 in Boston.
MBX-8025 is administered to
patients orally for the treatment of primary biliary cholangitis. It is
composed of peroxisome proliferator-activated receptor delta agonist
that is both potent and selective.
The presentation will be called “A phase 2 proof of concept
study of MBX-8025 in patients with Primary Biliary Cholangitis who are
inadequate responders to ursodeoxycholic acid” and has already been
published through the AASLD website.
Professor David Jones, Institute of
Cellular Medicine Professor of Liver Immunology, will present the results
of the trial on Nov. 15.
CymaBay to present results of MBX-8025 trial at AASLD annual meeting
Alerts Sign-up